The short version
- Why people research itMitochondrial ATP production, crista structure and cell survival in mitochondrial disease models, and now in a clinical trial for hearing loss in mitochondrial disease.
- What the evidence isNo publication exists — PubTator3 returns no phase 1 paper for this compound as of 29 September 2026.
- What to watchYellow skin or eyes, or dark urine, as signs of liver strain.
How MA-5 works
This molecule works on the shape of a membrane, not on the chemistry of a reaction, and that is what makes it worth a page. Suzuki 2015 names it in full: MA-5 is 4-(2,4-difluorophenyl)-2-(1H-indol-3-yl)-4-oxobutanoic acid.
One structural detail nobody in this category prints: there is a stereocenter at C-2. The indol-3-yl group and the hydrogen sit on the same carbon, so MA-5 exists as two enantiomers. The completed phase 1 listed MA-5 enantiomers among its secondary endpoints, which means the investigators treated the two forms as pharmacologically distinct and measured them separately.
MA-5 binds mitofilin (Mic60) at the crista junction, the core component of the mitochondrial inner-membrane organizing system, and that binding facilitates oligomerization of ATP synthase and supercomplex formation — which raises local ATP production and lowers mitochondrial reactive oxygen species without changing the activity of complexes I through IV. That is the unusual claim: it is not an antioxidant, not an uncoupler and not a biogenesis agent, and it raises ATP even when oxidative phosphorylation or electron transport is pharmacologically inhibited. It was found by screening an in-house library of analogs of the plant hormone indole-3-acetic acid for ATP elevation in Hep3B cells, so its parent scaffold is an auxin rather than a human metabolite. Downstream effects reported in models are reduced mitochondrial fragmentation, restored crista shape, and suppression of GDF-15 release under oxidative stress.
- Oral
On the goal map: Mitochondrial ATP production (Energy & fatigue)
Research on MA-511 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Human (Phase 1 complete, 58 healthy Japanese men, jRCT2031210495 — safety, tolerability and pharmacokinetics only, no publication; an investigator-initiated Phase 2 in 15 patients with mitochondrial disease and hearing loss began December 2025, jRCT2031250505, results not reported).
Human clinical evidence
A phase 1 is complete, and its results are in a registry rather than a journal. jRCT2031210495, running 18 January 2022 to 25 July 2023. Posted results: adverse events in 12.1% (7 of 58), no side effects attributed to the drug, no serious adverse events, no discontinuations for adverse events. No publication exists — PubTator3 returns no phase 1 paper for this compound as of 29 September 2026.
A phase 2 is running now, and it is small and specific. jRCT2031250505, registered 3 December 2025: an exploratory, placebo-controlled, double-blind, investigator-initiated Phase 2 in 15 patients aged 16-65 with mitochondrial disease accompanied by hearing loss, at four Japanese hospitals (Juntendo, Tohoku University, Tokyo Medical Center, Jichi Medical University). The endpoints are the useful part: auditory brainstem response, pure-tone audiometry from 125 to 8000 Hz, distortion-product otoacoustic emissions, hearing-related quality-of-life questionnaires, and blood GDF-15, FGF21, lactate and pyruvate, with pharmacokinetics at weeks 0 and 4 and secondary measures including MMSE, 6-minute walk distance, grip strength, eGFR and cardiac function.
What this does NOT amount to. A completed phase 1 establishes that healthy young men tolerated it for a week. It says nothing about efficacy, and the phase 2 has not reported. Anyone describing MA-5 as clinically supported is describing a trial that is underway, not a result. So the studied range is recorded here as not reliably read rather than quoted.
Correlative data
The human-tissue evidence is a fibroblast series, and it is the best-replicated part of the file. Across 25 patient fibroblast lines carrying various genetic mutations, 24 of 25 (96%) responded to MA-5. That is human cells from real patients rather than an immortalized line, and the breadth of genotypes is the point — the effect did not require a particular mutation.
The original patient series named the diseases specifically: fibroblasts from patients with Leigh syndrome, MELAS, Leber's hereditary optic neuropathy and Kearns-Sayre syndrome survived stress better with MA-5, and survival tracked the rise in cellular ATP.
GDF-15 is the bridge between the cells and the clinic, and it is already being used that way. MA-5 abrogated the significant increase in GDF-15 seen under oxidative stress, and the authors proposed GDF-15 as a useful diagnostic biomarker for clinical trials. The phase 2 now running lists blood GDF-15 and FGF21 among its endpoints — so the biomarker proposed in 2017 is the one being measured in patients in 2026, which is how a mechanism claim is supposed to mature.
How the mechanism reads
The binding target is named, localized and unusual. MA-5 targets mitofilin (Mic60) at the crista junction of the inner membrane, and overexpressing mitofilin in Hep3B cells raised basal ATP with MA-5 amplifying the effect. Mitofilin is the core of the mitochondrial inner-membrane organizing system — a structural protein, not an enzyme — so the claim is that MA-5 changes the geometry of the membrane the ATP synthase sits in.
MechanisticThe downstream claim is oligomerization, and it explains the strangest observation. MA-5 facilitates ATP synthase oligomerization and supercomplex formation with mitofilin/Mic60, reduces mitochondrial ROS, reduces mitochondrial fragmentation and restores crista shape — without affecting the activity of complexes I-IV, and while raising ATP even when oxidative phosphorylation or the electron transport chain is inhibited. That is why the authors insist it is not an antioxidant therapy: it is not scavenging anything, it is making the machine that makes ATP pack together more efficiently.
MechanisticThe mammalian in vivo record covers four organs and two injury models. In mito-mice carrying a large mtDNA deletion, MA-5 improved reduced cardiac and renal mitochondrial respiration and appeared to prolong survival — with the authors stating plainly that survival statistics could not be conducted. In an ischemia-reperfusion model and a cisplatin nephropathy model, MA-5 improved renal function. In a later mito-mouse study it inhibited progression of low body weight and lactic acidosis and protected renal respiration even when mutant mtDNA exceeded 80%. In transient middle-cerebral-artery occlusion in mice it reduced neurological deficits and infarct volume and suppressed the Bax/Bcl-2 ratio.
Experimental, animal or cellThe hearing result is the one the clinic followed. In Cdk5rap1-knockout mice, which develop early hearing loss through defective 2-methylthiolation of mitochondrial tRNAs, MA-5 improved auditory brainstem response thresholds and distortion-product otoacoustic emissions, reduced spiral-ganglion and outer-hair-cell loss, prevented mitochondrial degeneration in spiral ligament fibrocytes, raised SIRT1, promoted YAP nuclear translocation and reduced lactate accumulation. The phase 2's primary endpoints are the same two hearing measures used in that mouse study.
Experimental, animal or cellInvertebrate work adds breadth and one clean mechanistic control. In C. elegans, 10 microM MA-5 attenuated age-related decline in motor performance, loss of muscle mitochondria and degeneration of dopaminergic neurons associated with mitochondrial calcium overload. In a Duchenne model it alleviated movement decline, muscle tone, mitochondrial fragmentation and calcium accumulation; against rotenone it suppressed ROS, network fragmentation, nuclear destruction and ATP decline, and it protected dopaminergic CEP neurons. Most usefully, it reduced mitochondrial swelling caused by an immt-1 null mutation — immt-1 being the worm's mitofilin, which is the closest thing in this file to a genetic test of the proposed target.
Experimental, animal or cell
Sources
- Suzuki T, Yamaguchi H, Kikusato M, Matsuhashi T, Matsuo A, Sato T, Oba Y, Watanabe S, Minaki D, Saigusa D, Shimbo H, Mori N, Mishima E, Shima H, Akiyama Y, Takeuchi Y, Yuri A, Kikuchi K, Toyohara T, Suzuki C, Kohzuki M, Anzai J, Mano N, Kure S, Yanagisawa T, Tomioka Y, Toyomizu M, Ito S, Osaka H, Hayashi K, Abe T. Mitochonic Acid 5 (MA-5), a Derivative of the Plant Hormone Indole-3-Acetic Acid, Improves Survival of Fibroblasts from Patients with Mitochondrial Diseases. Tohoku Journal of Experimental Medicine 2015;236(3):225-32 · PMID 26118651
- Suzuki T, Yamaguchi H, Kikusato M, Hashizume O, Nagatoishi S, Matsuo A, Sato T, Kudo T, Matsuhashi T, Murayama K, Ohba Y, Watanabe S, Kanno S, Minaki D, Saigusa D, Shinbo H, Mori N, Yuri A, Yokoro M, Mishima E, Shima H, Akiyama Y, Takeuchi Y, Kikuchi K, Toyohara T, Suzuki C, Ichimura T, Anzai J, Kohzuki M, Mano N, Kure S, Yanagisawa T, Tomioka Y, Toyomizu M, Tsumoto K, Nakada K, Bonventre JV, Ito S, Osaka H, Hayashi K, Abe T. Mitochonic Acid 5 Binds Mitochondria and Ameliorates Renal Tubular and Cardiac Myocyte Damage. Journal of the American Society of Nephrology 2016;27(7):1925-32 · PMID 26609120
- Matsuhashi T, Sato T, Kanno SI, Suzuki T, Matsuo A, Oba Y, Kikusato M, Ogasawara E, Kudo T, Suzuki K, Ohara O, Shimbo H, Nanto F, Yamaguchi H, Saigusa D, Mukaiyama Y, Watabe A, Kikuchi K, Shima H, Mishima E, Akiyama Y, Oikawa Y, Hsin-Jung HO, Akiyama Y, Suzuki C, Uematsu M, Ogata M, Kumagai N, Toyomizu M, Hozawa A, Mano N, Owada Y, Aiba S, Yanagisawa T, Tomioka Y, Kure S, Ito S, Nakada K, Hayashi KI, Osaka H, Abe T. Mitochonic Acid 5 (MA-5) Facilitates ATP Synthase Oligomerization and Cell Survival in Various Mitochondrial Diseases. EBioMedicine 2017;20:27-38 · PMID 28579242
- Wu X, Nagasawa S, Muto K, Ueda M, Suzuki C, Abe T, Higashitani A. Mitochonic Acid 5 Improves Duchenne Muscular Dystrophy and Parkinson's Disease Model of Caenorhabditis elegans. International Journal of Molecular Sciences 2022;23(17):9572 · PMID 36076995
- Wu X, Seida M, Abe T, Higashitani A. Mitochonic acid 5 attenuates age-related neuromuscular dysfunction associated with mitochondrial Ca2+ overload in Caenorhabditis elegans. npj Aging 2023;9(1):20 · PMID 37528117
- Kouga T, Miwa T, Wei FY, Sunami K, Tomizawa K. Mitochonic acid 5 mitigates age-related hearing loss progression by targeting defective 2-methylthiolation in mitochondrial transfer RNAs. Frontiers in Cellular Neuroscience 2025;19:1541347 · PMID 40260078
- Sasaibe S, Yoshioka Y, Kuse Y, Nakamura S, Shimazawa M. Mitochonic acid 5, an ATP production accelerator, protects against neurological damage in ischemic stroke. Brain Research 2025;1860:149664 · PMID 40339682
- Ogasawara E, Tani H, Suzuki C, Owada Y, Ogata M, Ishihara N, Abe T, Nakada K. Effects of an indole chemical, mitochonic acid 5, in a mouse model of mitochondrial disease onset. Scientific Reports 2026; volume and pages not present in the PubTator3 record · PMID 42270754
MA-5 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Pregnancy or trying to conceive: no reproductive data exist for a drug that remodels the mitochondrial inner membrane.
- Under 18: the only human safety work so far is in adult men.
- Any current mitochondrial or ATP-synthase-targeting drug: stacked effects on the same machinery are unstudied.
- Active liver disease: it is an oral indole derivative cleared by the liver with no published data.
- Cancer history: more cellular ATP and less oxidative signaling also helps tumor cells.
What’s expected
- Often nothing felt, because the target is inner-membrane structure rather than a receptor.
- A possible lift in muscle or hearing-nerve energy supply if the mitofilin mechanism holds in people.
- Mild stomach upset is possible with any new oral small molecule.
Watch for
- Yellow skin or eyes, or dark urine, as signs of liver strain.
- Muscle pain or weakness that is new and builds.
- Ringing in the ears or change in hearing after starting.
- Persistent nausea that does not settle within days.
Labs that tell you it’s working
- Comprehensive Metabolic Panel (CMP)
- Cystatin C with eGFR
- Coenzyme Q10
- hs-CRP (C-Reactive Protein, High Sensitivity)
MA-5 binds mitofilin (Mic60) to organize ATP synthase; only a Phase 1 safety trial exists, so lines are predictions. PMID 26118651 PMID 28579242
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
MA-5 FAQ4 common questions
- Is MA-5 approved for human use?
- No. MA-5 is a research compound.
- What is MA-5 researched for?
- Mitochondrial ATP production, crista structure and cell survival in mitochondrial disease models, and now in a clinical trial for hearing loss in mitochondrial disease.
- Which labs show whether it's doing anything?
- Comprehensive Metabolic Panel; Cystatin C with eGFR; Coenzyme Q10; hs-CRP: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for MA-5: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



